Paper: “You Have Your Knowledge, but I Have My Knowledge of My Body”: The Hematologist-Patient Relationship and Enrollment of Black Participants in Clinical Trials

Oral and Poster Abstracts Oral 905. Outcomes Research—Lymphoid Malignancies: Patient Representation and Equity in Hematologic Malignancies Clinical Practice (Health Services and Quality), Diversity, Equity, and Inclusion (DEI) Shakira J. Grant, MBBS1,2, Milenka Jean-Baptiste, MPH3*, Mykela Moore, BA3*, Jiona Mills, BSPH3*, Lauren Bates, MA4*, Sascha A….

Read the full article here

Source: ash.confex.com

Categories: Hem/Oncs, Latest Headlines

Tweets with this article

Dr. Shakira J Grant MBBS

RT @ManniMD1: @ShakiraG_MBBS @stuchman1 https://t.co/JchDFOHaYC ^ and another excellent oral presentation by same group.

Paper: Global Access to Multiple Myeloma Medications (GLAMM-2 Study): Access and Barriers to Chemoimmunotherapies and Transplant

Program: Oral and Poster Abstracts Session: 652. Multiple Myeloma: Clinic al and Epidemiological: Poster III Hematology Disease Topics & Pathways: Research, Clinical Practice (Health Services…

Al-Ola A Abdallah MD April 18, 2024

Webprogram Unavailable

Please click HERE if you are not redirected in 5

Mike Thompson, MD, PhD, FASCO April 18, 2024

Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant…

Mike Thompson, MD, PhD, FASCO April 12, 2024

Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Mike Thompson, MD, PhD, FASCO April 9, 2024

Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Mike Thompson, MD, PhD, FASCO April 6, 2024

Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Mike Thompson, MD, PhD, FASCO March 21, 2024

Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Mike Thompson, MD, PhD, FASCO March 13, 2024

Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Mike Thompson, MD, PhD, FASCO March 11, 2024

Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Mike Thompson, MD, PhD, FASCO March 7, 2024

Paper: Comparing the Efficacy and Safety of Venetoclax Combined with Decitabine Versus Conventional Chemotherapy As Induction Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia – Interim Analysis of a Multicenter, Randomized, Phase 2b Trial

Program: Oral and Poster Abstracts Type: Oral Session: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Improving Intensive Chemotherapy Regimens for…

Faheema Hasan MD 👩‍⚕️ March 3, 2024

Related Articles